

Table 12.8
Adjusted Graft Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 5 Years, and 10 Years

	3 Months			1 Year			5 Years			10 Years		
	(Tx 2006 - 2007)			(Tx 2006 - 2007)			(Tx 2002 - 2007)			(Tx 1997 - 2007)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,855	91.8%	0.5%	2,855	82.2%	0.7%	7,503	50.6%	0.8%	12,085	24.8%	0.8%
Age at Tx												
<1 Year	8	88.8%	10.5%	8	82.3%	14.2%	22	50.3%	14.1%	44	27.9%	9.1%
1-5 Years	12	87.8%	8.5%	12	87.8%	8.5%	28	43.4%	13.6%	54	29.4%	8.3%
6-11 Years	19	100.0%	0.0%	19	97.0%	3.4%	55	59.5%	9.3%	106	19.4%	8.9%
12-17 Years	65	97.6%	1.7%	65	95.2%	2.4%	180	33.9%	5.7%	285	15.8%	3.6%
18-34 Years	360	94.4%	1.3%	360	86.3%	2.3%	951	46.8%	2.9%	1,566	29.6%	2.2%
35-49 Years	444	92.3%	1.2%	444	88.2%	1.5%	1,351	57.2%	1.8%	2,472	34.6%	1.6%
50-64 Years	1,560	91.1%	0.8%	1,560	79.6%	1.2%	4,190	51.0%	1.2%	6,654	21.2%	1.2%
65+ Years	387	89.0%	1.6%	387	74.9%	2.4%	726	45.6%	3.2%	904	13.7%	3.2%
Recipient Ethnicity/Race												
White	2,412	92.2%	0.5%	2,412	82.4%	0.8%	6,454	50.2%	0.9%	10,555	24.9%	0.9%
African American	245	90.2%	2.1%	245	81.5%	2.8%	575	54.8%	3.0%	889	23.4%	3.1%
Hispanic/Latino	148	87.5%	2.6%	148	79.0%	3.3%	348	48.5%	4.2%	475	29.7%	4.0%
Asian	29	93.2%	4.5%	29	76.3%	7.7%	81	58.0%	7.0%	108	21.7%	8.8%
Other/Multi-race	21	100.0%	0.0%	21	94.3%	5.4%	43	55.6%	9.8%	56	33.6%	9.9%
Unknown	0	-	-	0	-	-	2	+	+	2	+	+
Recipient Gender												
Female	1,230	92.3%	0.8%	1,230	82.2%	1.1%	3,437	50.7%	1.2%	5,754	25.0%	1.2%
Male	1,625	91.5%	0.7%	1,625	82.2%	1.0%	4,066	50.6%	1.2%	6,331	24.7%	1.1%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.

Cohorts are transplants performed during the years listed at the top of the table.

Graft survival follows individual transplants until graft failure. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.

Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.

Multi-organ transplants are excluded.

Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.

Table 12.8 (Continued)
Adjusted Graft Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 5 Years, and 10 Years

	3 Months			1 Year			5 Years			10 Years		
	(Tx 2006 - 2007)			(Tx 2006 - 2007)			(Tx 2002 - 2007)			(Tx 1997 - 2007)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,855	91.8%	0.5%	2,855	82.2%	0.7%	7,503	50.6%	0.8%	12,085	24.8%	0.8%
Primary Diagnosis												
Emphysema/COPD	868	94.2%	0.8%	868	85.7%	1.2%	2,583	52.5%	1.4%	4,523	22.6%	1.3%
Cystic Fibrosis	442	91.0%	1.8%	442	77.1%	3.0%	1,174	48.8%	2.5%	1,933	28.1%	2.0%
Idiopathic Pulmonary Fibrosis	888	90.7%	1.0%	888	80.1%	1.4%	2,005	48.3%	1.8%	2,723	23.9%	2.0%
Alpha-1-Antitrypsin Deficiency	90	94.6%	2.4%	90	89.1%	3.2%	354	60.3%	3.1%	740	25.5%	2.7%
Idiopathic Pulmonary Arterial Hypertension	63	86.2%	4.8%	63	84.3%	5.1%	231	52.6%	4.2%	438	30.3%	3.6%
Congenital Disease	2	100.0%	0.0%	2	44.7%	23.2%	31	41.6%	9.2%	98	29.1%	5.5%
Other	502	89.5%	1.4%	502	80.9%	1.8%	1,124	54.3%	2.2%	1,627	33.6%	2.2%
Unknown	0	-	-	0	-	-	1	+	+	3	34.1%	20.6%
Lung Diagnosis Group												
Group A: Obstructive Lung Disease	1,092	91.9%	2.8%	1,092	81.1%	5.9%	3,311	40.0%	5.1%	5,848	16.3%	2.8%
Group B: Pulmonary Vascular Disease	102	91.7%	7.0%	102	86.2%	11.1%	307	50.8%	14.2%	554	30.3%	8.8%
Group C: Cystic Fibrosis or Immunodef. Disorders	438	88.5%	10.8%	438	72.6%	22.9%	1,152	53.4%	11.2%	1,883	32.9%	7.3%
Group D: Restrictive Lung Disease	1,164	93.4%	1.9%	1,164	85.9%	3.7%	2,566	59.0%	3.9%	3,476	32.1%	3.5%
Group E: Age Less Than 12	39	72.3%	17.7%	39	60.5%	21.3%	105	60.7%	8.1%	204	37.7%	7.1%
Other Diagnosis	20	94.5%	5.5%	20	94.5%	5.5%	62	63.5%	8.2%	120	28.5%	8.0%
Lung Allocation Score												
LAS 0	5	65.8%	23.5%	5	65.8%	23.5%	0	-	-	0	-	-
LAS 20 - 29	20	82.8%	8.6%	20	82.8%	8.6%	0	-	-	0	-	-
LAS 30 - 34	969	93.7%	0.8%	969	85.5%	1.3%	0	-	-	0	-	-
LAS 35 - 39	740	93.3%	0.9%	740	82.9%	1.4%	0	-	-	0	-	-
LAS 40 - 49	627	90.7%	1.2%	627	80.9%	1.7%	0	-	-	0	-	-
LAS 50 - 59	187	92.6%	1.9%	187	84.4%	2.6%	0	-	-	0	-	-
LAS 60+	307	84.7%	2.1%	307	70.7%	2.7%	0	-	-	0	-	-
Unknown	0	-	-	0	-	-	7,503	50.6%	0.8%	12,085	24.8%	0.8%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.

Cohorts are transplants performed during the years listed at the top of the table.

Graft survival follows individual transplants until graft failure. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.

Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.

Multi-organ transplants are excluded.

Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.

Table 12.8 (Continued)
Adjusted Graft Survival, Deceased Donor Lung Transplants
Survival at 3 Months, 1 Year, 5 Years, and 10 Years

	3 Months			1 Year			5 Years			10 Years		
	(Tx 2006 - 2007)			(Tx 2006 - 2007)			(Tx 2002 - 2007)			(Tx 1997 - 2007)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	2,855	91.8%	0.5%	2,855	82.2%	0.7%	7,503	50.6%	0.8%	12,085	24.8%	0.8%
Transplant Center State												
Alabama	61	91.0%	3.5%	61	79.7%	5.0%	167	42.3%	5.1%	328	24.9%	4.7%
Arizona	45	86.5%	5.1%	45	79.7%	6.0%	74	58.0%	7.7%	98	25.7%	9.7%
California	351	93.7%	1.2%	351	84.6%	1.9%	958	47.8%	2.4%	1,381	21.8%	2.5%
Colorado	65	94.0%	2.9%	65	87.8%	4.0%	208	45.9%	4.6%	346	22.0%	4.1%
Florida	241	92.3%	1.7%	241	85.6%	2.2%	534	55.8%	3.2%	686	22.4%	4.6%
Georgia	52	92.6%	3.5%	52	83.2%	5.0%	136	43.6%	6.8%	191	22.1%	5.3%
Iowa	5	+	+	5	+	+	5	+	+	5	+	+
Illinois	87	92.3%	2.8%	87	79.5%	4.3%	215	54.7%	5.3%	394	23.6%	5.3%
Indiana	66	85.2%	4.3%	66	70.3%	5.6%	234	42.9%	4.6%	346	12.4%	4.2%
Kentucky	46	97.9%	2.0%	46	83.3%	5.3%	125	35.1%	6.6%	224	8.7%	3.9%
Louisiana	0	-	-	0	-	-	59	48.8%	6.6%	155	15.0%	3.9%
Massachusetts	63	90.3%	3.8%	63	74.0%	5.6%	196	42.1%	4.9%	335	21.2%	4.0%
Maryland	73	90.3%	3.2%	73	80.3%	4.4%	168	42.4%	5.8%	290	34.8%	3.9%
Michigan	73	88.2%	3.7%	73	80.2%	4.6%	196	55.3%	5.1%	388	24.5%	4.0%
Minnesota	107	94.4%	2.2%	107	87.0%	3.2%	275	56.8%	4.6%	455	30.6%	3.9%
Missouri	139	92.1%	2.4%	139	82.5%	3.4%	408	60.9%	3.1%	771	36.3%	2.8%
North Carolina	138	93.1%	2.1%	138	80.5%	3.4%	418	51.5%	3.5%	759	25.2%	3.0%
Nebraska	0	-	-	0	-	-	0	-	-	14	21.1%	10.9%
New Jersey	0	-	-	0	-	-	0	-	-	3	0.0%	0.0%
New York	128	94.0%	2.1%	128	84.7%	3.1%	272	52.4%	5.3%	400	25.8%	5.1%
Ohio	148	92.9%	2.1%	148	86.4%	2.8%	412	51.8%	3.5%	626	22.9%	3.5%
Oklahoma	19	89.2%	6.9%	19	62.0%	11.0%	88	23.0%	5.8%	118	16.7%	4.6%
Oregon	0	-	-	0	-	-	0	-	-	8	13.1%	10.9%
Pennsylvania	374	90.4%	1.5%	374	78.5%	2.1%	829	54.0%	2.4%	1,284	26.2%	2.4%
South Carolina	0	-	-	0	-	-	0	-	-	1	0.0%	0.0%
Tennessee	39	79.0%	6.4%	39	62.7%	7.8%	118	42.2%	5.5%	211	26.5%	4.0%
Texas	221	89.7%	2.0%	221	82.3%	2.6%	574	46.6%	2.9%	916	22.8%	2.6%
Utah	18	94.5%	5.2%	18	94.5%	5.2%	54	48.6%	9.6%	99	22.8%	6.4%
Virginia	115	94.0%	2.2%	115	83.7%	3.4%	299	54.8%	4.3%	486	21.4%	3.8%
Washington	104	94.5%	2.2%	104	88.0%	3.1%	262	55.2%	4.7%	371	16.9%	6.3%
Wisconsin	77	91.0%	3.2%	77	84.4%	4.1%	219	66.5%	3.9%	396	33.2%	4.8%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.

Cohorts are transplants performed during the years listed at the top of the table.

Graft survival follows individual transplants until graft failure. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.

Center volume = Center's yearly transplants performed during the base period, based on lung and heart-lung transplants.

Multi-organ transplants are excluded.

Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.